The rising interest in GLP-1 agonists for diabetes has led to a question about formats: skin-applied devices versus capsules. Traditionally , GLP-1 treatments were only available in tablet form, but the development of transdermal delivery offers a different option . Patches might be advantageous for individuals facing challenges with oral medicatio